v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Jan. 31, 2026
Jan. 31, 2025
Cash flows from operating activities:        
Net loss $ (1,511,930) $ (682,888) $ (3,074,964) $ (5,137,332)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock-based compensation 345,000 277,500 1,454,167 2,966,115
Amortization of debt discount 36,801 7,006 19,490
Change in assets and liabilities:        
Prepaid expenses (40,884) (65,735) 71,764 (82,882)
Other receivable 35,000 3,644 (31,356)
Accounts payable and accrued expenses 225,689 46,367 153,563 (176,573)
Accounts payable and accrued expenses - related party (35,613) 66,012 212,700 (366,295)
Accrued interest 90,879 129,133 388,517 273,969
Net cash used in operating activities (855,058) (225,967) (818,603) (2,503,508)
Cash flows from financing activities:        
Proceeds from convertible notes payable 1,255,000    
Proceeds from note payable 25,000 249,258 100,000
Proceeds from notes payable to related party 100,000 209,000
Repayment of debenture (250,000) (5,000)
Proceeds from exercise of warrants 108,000 283,941 384,000
Repayment of notes payable (110,000)    
Net cash provided by financing activities 995,000 133,000 742,199 2,574,040
Net (decrease) increase in cash 139,942 (92,967) (76,404) 70,532
Cash at beginning of period 24,274 100,678 100,678 30,146
Cash at end of period 164,216 7,711 24,274 100,678
Cash paid for interest 37,814 11,785 93,460 110,712
Cash paid for taxes
Non-cash investing and financing activities:        
Conversion of convertible notes payable 102,947 1,048,793
Issuance of warrants for convertible notes payable 780,854    
Deferred offering costs $ 133,082    
Proceeds from sale of preferred stock, net     2,095,040
Cashless exercise of warrants and options     20,563
Conversion of accounts payable into common stock     $ 30,000